Primary care physicians and musculoskeletal disorders - The challenges increase

Journal of Rheumatology

Volumn 33, Issue 1, 2006, Pages 4-5

  Flook, Nigel W ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOOXYGENASE 2 INHIBITOR; MISOPROSTOL; NONSTEROID ANTIINFLAMMATORY AGENT;

CANADA; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; DIAGNOSTIC ACCURACY; DRUG SAFETY; EDITORIAL; GASTROINTESTINAL DISEASE; HEALTH CARE SYSTEM; HEALTH INSURANCE; HELICOBACTER PYLORI; HOSPITAL BILLING; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; KIDNEY FUNCTION; MEDICAL PRACTICE; MUSCULOSKELETAL DISEASE; PATIENT CODING; PHYSICIAN; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK; TREATMENT OUTCOME;

CANADA; DATABASES, FACTUAL; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; MUSCULOSKELETAL DISEASES; PHYSICIAN'S PRACTICE PATTERNS; PHYSICIANS, FAMILY;

EID: 30144435396     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Editorial

References (12)

1. Power JD, Perruccio AV, DesMeules M, Lagacé C, Badley EM. Ambulatory physician care for musculoskeletal disorders in Canada. J Rheumatol 2006;33:133-9.
2. Health Canada. Arthritis in Canada [Report on the Internet. 2003. Accessed November 1, 2005. 124 pages.] Available from: http://www.phac-aspc.gc. ca/publicat/ac/index.html
3. Akesson K, Dreinhofer KE, Woolf AD. Improved education in musculoskeletal conditions is necessary for all doctors. Bull World Health Organ 2003;81:677-83.
4. National Physician Survey, 2004 Results. College of Family Physicians of Canada. [Internet Survey. Accessed November 1, 2005.] Available from: http://www.cfpc.ca/English/cfpc/research/janus%20project/nps/resul ts/default.asp?s=1
5. Davis P, Juby A, Robertson S, Richard N. Is there anything else we could possibly need to know about COX-2 selective inhibitor drugs? [editorial]. J Rheumatol 2004;31:847-8.
6. US Food and Drug Administration. FDA Joint Meeting of the Arthritis Advisory Committee and Drug Safety Committee, February 16-18, 2005. [Meeting records on the Internet. Accessed November 1, 2005.] Available from: http://www.fda.gov/ohrms/dockets/ac/cder05.html.
7. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1995;123:241-9.
8. Tramer MR, Moore RA, Reynolds DJ, McQuay HJ. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain 2000;85:169-82.
9. Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet 2002;359:14-22.
10. Kelly JP, Kaufman DW, Jurgelon JM, Sheehan J, Koff RS, Shapiro S. Risk of aspirin-associated major upper-gastrointestinal bleeding with enteric-coated or buffered product. Lancet 1996;348:1413-6.
11. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001;344:967-73.
12. Stack WA, Atherton JC, Hawkey GM, Logan RF, Hawkey CJ. Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther 2002;16:497-506.